![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
CAMPATH® (CAMPATH-1H, alemtuzumab, MabCAMPATH), is a lymphocyte-depleting humanized monoclonal antibody that was recently approved in the USA and Europe for the treatment of chronic lymphocytic leukemia (CLL). It targets CD52 – a small glycosylphosphatidylinositol-anchored glycoprotein that is highly expressed on normal T- and B-lymphocytes and on a large proportion of lymphoid cell malignancies – but not on hematopoietic progenitor cells. CAMPATH was shown to be effective against CLL refractory to chemotherapy with an acceptable toxicity profile. CAMPATH is also active against T-cell prolymphocytic leukemia and has been extensively used to prevent graft-versus-host disease associated with bone marrow transplantation. CAMPATH is owned by ILEX Pharmaceuticals LP and distributed by Schering AG and its US affiliate Berlex Laboratories.
- antibody-dependent-cellular cytotoxicity
- apoptosis
- bone marrow transplantation
- CAMPATH (alemtuzumab MabCAMPATH)
- CD52 antigen
- chronic lymphocytic leukemia
- complement-dependent cytolysis
- first-dose reaction
- fludarabine
- immunosuppression
- lymphoid malignancies
- lymphopenia
- monoclonal antibody
- non-Hodgkin lymphoma
- rituximab
- T-cell prolymphocytic leukemia